For a pT3 N0 rectal cancer patient after low anterior resection, should adjuvant systemic chemotherapy be given before postoperative chemoradiotherapy, or should chemoradiotherapy be administered first?

Postoperative Adjuvant Chemotherapy Should Be Given First, Followed by Chemoradiotherapy

For a pT3 N0 rectal cancer patient after low anterior resection who did not receive preoperative therapy, the standard approach is to administer one cycle of systemic chemotherapy first, then concurrent chemoradiotherapy, followed by additional cycles of chemotherapy. This "sandwich" approach is the established postoperative treatment sequence for patients who did not undergo neoadjuvant therapy 1, 2.

The Evidence-Based Sequencing

The NCCN guidelines explicitly outline the postoperative adjuvant regimen for patients not receiving preoperative therapy 1:

• Start with 5-FU/leucovorin × 1 cycle (6 weeks of treatment followed by 2 weeks rest)
• Then proceed to concurrent chemoradiotherapy (45-50.4 Gy with concurrent 5-FU-based radiosensitization)
• Complete with 5-FU/leucovorin × 2 additional cycles

This sequencing allows early initiation of systemic therapy to address potential micrometastatic disease while maintaining the benefits of chemoradiotherapy for local control.

Why This Sequence Matters

Preoperative therapy is strongly preferred over postoperative treatment when feasible 3, 4. The landmark German CAO/ARO/AIO-94 trial demonstrated that preoperative chemoradiotherapy significantly reduces local recurrence (6% vs 13%, P=0.006) and treatment-associated toxicity (27% vs 40%, P=0.001) compared to postoperative therapy, though overall survival was similar 3, 4.

However, since your patient already underwent surgery without neoadjuvant therapy, you're now in the postoperative setting where the established sequence is chemotherapy-first.

Important Considerations for pT3 N0 Disease

The routine use of postoperative chemoradiotherapy for all pT3 N0 tumors has been questioned 2. The ESMO guidelines note that traditionally all pT3-4 or N+ tumors received postoperative chemoradiotherapy, but this has been challenged for pT3 N0 disease specifically 2.

For your pT3 N0 patient, postoperative chemoradiotherapy should be considered if:

• Positive circumferential margins (CRM+)
• Perforation in the tumor area
• Other high-risk features suggesting elevated local recurrence risk
• The tumor was in the lower rectum where local control is more challenging

If the resection margins were clear (R0), the tumor was in the upper rectum, and there are no other high-risk features, adjuvant chemotherapy alone may be sufficient 2, 5.

The Adjuvant Chemotherapy Evidence

The benefit of adjuvant chemotherapy after preoperative chemoradiotherapy and surgery is uncertain 6. A meta-analysis of 1,196 patients found no significant improvement in overall survival (HR 0.97, P=0.775), disease-free survival (HR 0.91, P=0.230), or distant recurrences (HR 0.94, P=0.523) with adjuvant chemotherapy versus observation 6.

However, this evidence applies to patients who received preoperative therapy. For patients treated with postoperative chemoradiotherapy (your scenario), the completion of the full chemotherapy regimen remains standard practice, though adherence to postoperative chemotherapy is notably poor (42.9% vs 82.0% for preoperative) 7.

Practical Algorithm

For your pT3 N0 post-LAR patient:

1. Assess risk factors:

   • CRM status (positive = high risk)
   • Tumor location (lower rectum = higher risk)
   • Lymphovascular invasion, poor differentiation
   • Quality of TME specimen

2. If high-risk features present:

   • Begin 5-FU/leucovorin × 1 cycle
   • Proceed to chemoradiotherapy (45-50.4 Gy with concurrent 5-FU)
   • Complete with 5-FU/leucovorin × 2 cycles

3. If low-risk (upper rectum, clear margins, good TME, no adverse features):

   • Consider chemotherapy alone (similar to colon cancer approach)
   • FOLFOX or CAPEOX for 6 months may be reasonable 1

Critical Pitfall to Avoid

Do not delay treatment initiation. The total duration of perioperative therapy should not exceed 6 months 4. Starting with chemotherapy allows you to begin systemic treatment promptly while planning radiation therapy, which requires simulation and treatment planning time.

The key distinction is that preoperative therapy is superior to postoperative therapy 3, 4, so this entire discussion represents a suboptimal situation that arose from not treating preoperatively. The chemotherapy-first sequence in the postoperative setting represents the best salvage approach for a patient who missed the opportunity for neoadjuvant treatment.